Track all markets on TradingView
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Media

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

  • November 6, 2024
  • 10 Views

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025.

Latest Ratings for EXAS

Date Firm Action From To
Feb 2022 Wells Fargo Maintains Equal-Weight
Feb 2022 Citigroup Maintains Neutral
Feb 2022 Raymond James Maintains Outperform

View More Analyst Ratings for EXAS

View the Latest Analyst Ratings

read more

​ 

​Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025.

Latest Ratings for EXAS
DateFirmActionFromTo Feb 2022Wells FargoMaintainsEqual-Weight Feb 2022CitigroupMaintainsNeutral Feb 2022Raymond JamesMaintainsOutperform
View More Analyst Ratings for EXAS

View the Latest Analyst Ratings

read more 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.